Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

JAMA oncology - 1 Aug 2015

Pardanani Animesh, Harrison Claire, Cortes Jorge E, Cervantes Francisco, Mesa Ruben A, Milligan Donald, Masszi Tamás, Mishchenko Elena, Jourdan Eric, Vannucchi Alessandro M, Drummond Mark W, Jurgutis Mindaugas, Kuliczkowski Kazimierz, Gheorghita Emanuil, Passamonti Francesco, Neumann Frank, Patki Abhay, Gao Guozhi, Tefferi Ayalew

Abstract excerpt

IMPORTANCE: Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival. Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in early-phase trials. OBJECTIVE: To evaluate the efficacy and safety of fedratinib therapy in patients with primary or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Organ Size

Share to Primary Myelofibrosis

Share to Pyrrolidines

Share to Splenomegaly

Share to Sulfonamides

Source

Identifiers

PMID: 26181658
DOI: 10.1001/jamaoncol.2015.1590

Genes

BCR
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.PMID 26181658Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Semantic proximity Read ↗

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Efficacy of ruxolitinib for myelofibrosis.Semantic proximity Read ↗

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.Semantic proximity Read ↗

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity Read ↗

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.Semantic proximity Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.